{"organizations": [], "uuid": "32ff92c603bcfe4b50c498bd60182b52c511ed87", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-newlink-genetics-outlines-2018-bus/brief-newlink-genetics-outlines-2018-business-priorities-idUSASB0C03C", "country": "US", "domain_rank": 408, "title": "BRIEF-Newlink Genetics Outlines 2018 Business Priorities", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.106, "site_type": "news", "published": "2018-01-08T21:13:00.000+02:00", "replies_count": 0, "uuid": "32ff92c603bcfe4b50c498bd60182b52c511ed87"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-newlink-genetics-outlines-2018-bus/brief-newlink-genetics-outlines-2018-business-priorities-idUSASB0C03C", "ord_in_thread": 0, "title": "BRIEF-Newlink Genetics Outlines 2018 Business Priorities", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "newlink genetics corp", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Newlink Genetics Corp:\n* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS\n* NEWLINK GENETICS CORP - ENDED 2017 WITH APPROXIMATELY $158 MILLION IN CASH AND CASH EQUIVALENTS\n* NEWLINK GENETICS - ENTERING 2018, HAVE ALIGNED BUSINESS AND INVESTMENTS TO DRIVE INDIGO301 AND OTHER HIGH-POTENTIAL DEVELOPMENT PROGRAMS\n* NEWLINK GENETICS CORP - ENROLL MAJORITY OF INDIGO301 TRIAL BY END OF 2018\n* NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + PD-1 BLOCKADE IN ADVANCED MELANOMA EXPECTED IN 2018\n* NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + GEM/NAB-PACLITAXEL IN PANCREATIC CANCER EXPECTED 1H 2018\n* NEWLINK GENETICS CORP - PHASE 2 RANDOMIZED ASTRAZENECA COLLABORATION IN PANCREATIC CANCER TO INITIATE 1H 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:13:00.000+02:00", "crawled": "2018-01-09T16:53:26.009+02:00", "highlightTitle": ""}